We are live on ! Find out more
IMGN

Immunogen Inc
IMGN

Delisted

IMGN was delisted on the 9th of February, 2024.

Back to rankings

204 hedge funds and large institutions have $1.1B invested in Immunogen Inc in 2018 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 59 increasing their positions, 69 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more capital invested

Capital invested by funds: $666M → $1.1B (+$438M)

19% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 37

2% more funds holding

Funds holding: 200 → 204 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

14% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 69

68% less call options, than puts

Call options by funds: $8.85M | Put options by funds: $27.5M

Holders
204
Holders Change
+4
Holders Change %
+2%
% of All Funds
4.68%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
44
Increased
59
Reduced
69
Closed
37
Calls
$8.85M
Puts
$27.5M
Net Calls
-$18.6M
Net Calls Change
-$20.2M

Top Buyers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
+$54.4M
2
Renaissance Technologies
Renaissance Technologies
New York
+$36.7M
3
PC
PointState Capital
New York
+$16.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.79M
5
Goldman Sachs
Goldman Sachs
New York
+$6.89M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$16.4M
2
ClearBridge Investments
ClearBridge Investments
New York
-$14.7M
3
O
OrbiMed
New York
-$13.1M
4
Millennium Management
Millennium Management
New York
-$12.9M
5
RG
Redmile Group
California
-$11.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
$8.98M +$1.38M +139,633 +20%
Arrowstreet Capital
27
Arrowstreet Capital
Massachusetts
$7.26M +$4.23M +428,503 +164%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$7.2M +$898K +90,900 +15%
TCIM
29
TIAA CREF Investment Management
New York
$6.74M -$784K -79,397 -11%
RJA
30
Raymond James & Associates
Florida
$6.58M +$58.7K +5,942 +1%
CS
31
Candriam SCA
Luxembourg
$6.25M +$237K +24,000 +4%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$6.21M +$1.05M +106,522 +22%
Charles Schwab
33
Charles Schwab
California
$5.59M +$80.1K +8,112 +2%
CEP
34
Chicago Equity Partners
Illinois
$5.3M +$145K +14,730 +3%
UBS Group
35
UBS Group
Switzerland
$5.01M +$3.67M +371,886 +356%
Citadel Advisors
36
Citadel Advisors
Florida
$4.76M +$2.86M +289,783 +178%
EI
37
EAM Investors
California
$3.95M +$3.71M +375,205 New
Allianz Asset Management
38
Allianz Asset Management
Germany
$3.93M +$1.42M +144,261 +63%
Norges Bank
39
Norges Bank
Norway
$3.51M – – –
TI
40
Trexquant Investment
Connecticut
$3.48M +$2.15M +217,244 +191%
Citigroup
41
Citigroup
New York
$3.24M -$1.41M -142,763 -32%
BIM
42
Bogle Investment Management
Massachusetts
$2.87M +$2.69M +272,592 New
Natixis Advisors
43
Natixis Advisors
Massachusetts
$2.49M -$433K -43,789 -16%
Two Sigma Investments
44
Two Sigma Investments
New York
$2.35M -$7.87M -796,873 -78%
GCP
45
GSA Capital Partners
United Kingdom
$2.31M -$507K -51,334 -19%
Swiss National Bank
46
Swiss National Bank
Switzerland
$2.3M +$567K +57,400 +36%
GC
47
Guggenheim Capital
Illinois
$2.16M -$624K -63,167 -23%
Wellington Management Group
48
Wellington Management Group
Massachusetts
$2.13M -$2.01M -203,923 -50%
FIM
49
Fernwood Investment Management
Massachusetts
$2.04M -$306K -31,000 -14%
Jacobs Levy Equity Management
50
Jacobs Levy Equity Management
New Jersey
$1.93M -$1.67M -169,190 -48%
1
2
3 4 5

IMGN Hedge Fund Activity: Q1 2018 in Review

204 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q1 2018, worth a combined $1.1B — up 66% from $666M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new IMGN positions and 37 closed out — a net gain of 7 holders — while 59 added to existing stakes and 69 trimmed.

The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $54.4M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $16.4M sold.

  • 204 institutional investors held Immunogen Inc (IMGN) as of Q1 2018, up from 200 in Q4 2017.
  • Funds reported $1.1B of Immunogen Inc stock for Q1 2018, up 66% quarter-over-quarter.
  • 44 funds opened new Immunogen Inc positions in Q1 2018 and 37 closed out, a net change of +7 holders.
  • The largest Immunogen Inc buyer in Q1 2018 was Capital Research Global Investors, an estimated $54.4M added.
  • The largest Immunogen Inc seller in Q1 2018 was Baker Bros. Advisors, an estimated $16.4M sold.

Based on aggregated 13F filings for Q1 2018.